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The importance of adequate anticoagulation to 
prevent early thrombosis after stenting of 
stenosed venous bypass grafts 
Stent implantation in native coronary arteries may be complicated by acute thrombosis, despite 
the use of stringent anticoagulation. Thrombotic occlusion of stented venous grafts may occur 
less frequently, possibly because of the larger caliber of these grafts. We report our experience 
with 46 stents (Wallstent, Medinvent, Lausanne, Switzerland) implanted in 35 lesions of 24 
consecutive patients (mean age 64 years, range 43 to 75). Two overlapping stents were 
implanted in seven patients, and three overlapping stents were positioned in two. After 
implantation, activated partial thromboplastin time was maintained at two to three times the 
control level by intravenous administration of heparin (160 to 550 mg daily) until thrombotest 
values were reduced 5% to 10% by acenocoumarol. Impending thrombotic occlusion was 
recognized in two suboptimally anticoagulated patients: patient A after implantation of four 
stents and patient B after anticoagulation therapy was discontinued because of acute upper 
gastrointestinal bleeding. Coronary artery bypass grafting was performed successfully in both 
patients. A third patient had a myocardial infarction on day 7 after stent implantation, in spite of 
adequate anticoagulation and optimal medical drug therapy. It is concluded that stringent 
anticoagulation therapy appears mandatory to maintain graft patency after stent implantation. 
(AM HEART J lQQ1;121:136g.) 
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Patients with venous bypass grafts are at risk of hav- 
ing atherosclerotic degeneration of the graft.lV3 Both 
short- and long-term results after balloon dilatation 
of this type of lesion, and notably angioplasty of 
completely occluded grafts, appear to be less favor- 
able than results in native coronary arteries.4-6 In 
approximately 3 % of patients the procedure may be 
complicated by peripheral embolization of the by- 
pass atheroma, resulting in peripheral occlusion and 
myocardial infarction. 4, 6 The restenosis rate in di- 
lated venous bypass grafts is higher than that in na- 
tive vessels; particularly the proximal anastomosis is 
prone to restenosis (46 % 1, the risk is intermediate in 
the shaft of the vein graft (35%) and lowest at the 
distal anastomosis (24% ).8 It has been reported that 
only 46% of patients were symptom free 5 years 
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after angioplasty of a saphenous vein graft compared 
with 79% after balloon dilatation of native ves- 
sels.g 
Recently it has been suggested that stent implan- 
tation at the dilatation site may improve both short- 
and long-term results. 1o,11 Evaluation of the use of 
these devices may be even more appealing in view of 
the increasing number of patients that have recur- 
rent angina after venous bypass grafting.g The aim of 
this analysis was to assess the need for anticoagula- 
tion therapy to prevent thrombotic complications 
after successful stent implantation in venous bypass 
grafts. Obviously the risk of complications inherent 
in anticoagulation therapy should compare favorably 
with the possible gain in safety, improved success 
rate, and better immediate hemodynamic results 
when these new interventions are applied in a high- 
risk patient population. 
METHODS 
Patients. The patient population consisted of 24 con- 
secutive patients who had previously undergone venous 
aortocoronary bypass surgery and had recurrent angina 
pectoris (Canadian Heart Association class III to IV). The 
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Table I. Drug treatment before and 3 months after stent 
implantation 
Before 
Drug implantation 3 mo after 
Nitrates 9 4 
NTG 3 3 
/j-Blockers 12 11 
Ca++ entry blockers 16 14 
Phenprocoumon/Acenocoumarin 9 19 
Aspirin I1 20 
Dipyridamole 7 21 
Sulfinpyrazone 2 4 
ACE inhibitors 3 4 
Digoxin 3 3 
Diuretics 6 3 
Antiarrhythmic drugs 2 3 
NTG. Nitroglycerin 
complaints were typical and were documented by ST seg- 
ment abnormalities either at rest or during exercise. 
Symptoms had to have been present for more than 7 days 
and unresponsive to maximal drug treatment without signs 
of recent myocardial infarction. All patients were discussed 
with the cardiothoracic surgeon and were considered not to 
be good candidates for reoperation on the basis of their 
coronary anatomy and the expected gain from surgery. In 
view of the stringent anticoagulation that had to be applied 
after stent implantation, all patients were screened for the 
presence of any bleeding disorders. For this reason patients 
with recent gastrointestinal bleeding, cerebrovascular ac- 
cident, or other bleeding disorders did not undergo stent 
implantation. This report focuses on elective procedures; 
therefore two patients with evolving myocardial infarction 
and two with stent implantation in an occluded bypass at 
the time of the study will not be discussed. The mean age 
of the 20 men and four women was 63.6 years (+ 9.4). Six 
patients had hypertension and five had hypercholester- 
olemia. Diabetes mellitus was diagnosed in seven patients; 
three patients were insulin dependent, three were taking 
oral medication, and one was following a sugar-free diet. 
Three patients were current smokers. The average ejection 
fraction was 56% (range 0.26 to 0.70). 
The implantation procedure is described in detail 
elsewhere.13-l5 In seven patients the stent was implanted 
without angioplasty, and in 21 the implantation was 
preceded by balloon angioplasty. In five patients balloon 
angioplasty was performed before and after stent implan- 
tation; in the remaining five the lesion was stented and an- 
gioplasty was subsequently performed in the stented artery 
(“Swiss kiss”). Catheters were introduced either viasheaths 
in the femoral artery by percutaneous puncture according 
to the Seldinger technique (n = 22) or by direct dissection 
of the brachial artery (n = 2). At the end of the procedure 
the brachial vessels were surgically closed. Femoral sheaths 
were left in place during the ensuing 24 hours; the next day 
the sheaths were removed 2 hours after heparin was 
discontinued; 1 hour later heparin was resumed. 
The average interval since the last bypass surgery was 
72.8 months (range 1 to 166). The average number of by- 
pass grafts was 1.4 (range 1 to 3). Thirty-five lesions were 
stented with 46 stents; the stenosis was located in the os- 
tium in four patients, in the shaft in 21, at the proximal 
anastomosis in six, and distally in five. In seven patients 
two stents were positioned in a telescoping manner, and in 
two patients three overlapping stents were implanted. In 
the remaining patients, one prosthesis was positioned at 
the stenosis. Medication given before stent implantation 
and at 3 months’ follow-up is summarized in Table I. Nine 
patients were receiving anticoagulation therapy (aceno- 
coumarin or phenprocoumon) before stent implantation 
and 19 at 3 months’ follow-up. 
Drug protocol before, during, and after implantation. 
The protocol for drug treatment consisted of administra- 
tion of oral dipyridamole (4 x 75 mg), sulfinpyrazone 
(4 X 200 mg), and salicylic acid (2 X 500 mg on the day be- 
fore implantation and 1 X 100 mg thereafter), as well as 
nifedipine (3 x 20 mg), which was started before stent im- 
plantation and continued for approximately 3 months 
(Table II). Before balloon dilatation heparin, 10,000 IU, 
and dextran, 500 mg/4 hr, were given intravenously. 
Immediately after stent implantation 100,000 to 250,000 
IU of urokinase was administered intracoronarily, followed 
by an additional 100,000 IU during the next 60 minutes. 
Intravenous heparin was continued at a minimal dosage of 
24,000 IU/24 hr; the dosage was adjusted to double or tri- 
ple the activated partial thromboplastin time (APTT). If 
the APTT exceeded 180 seconds, the infusion was inter- 
rupted for 1 hour and resumed at a dosage that was 
decreased by 5000 IU/24 hr. Heparin was continued but the 
dosage was reduced by 5000 IU/24 hr when the APTT was 
between 120 and 180 seconds. If the APTT was less than 
70 seconds or twice control values, the dosage was increased 
by 5000 IU/24 hr and the APTT was controlled 8 hours 
later. Oral acenocoumarol was started on the day of 
implantation; heparin infusion was continued until pro- 
thrombin time measured by thrombotest (TT) was lowered 
to 5 ?; to 10 % for two subsequent days and was slowly dis- 
continued thereafter. 
intravascular stent. The self-expanding stent consisted Baseline hemostatic parameters. Twelve hours before 
of 16 metal alloy filaments (outer diameter 0.08 mm) that 
formed a geometrically stable tubular meshwork; the max- 
imal outer diameter of the device that was attained after 
implantation was determined on the one hand from the ra- 
dial forces generated by the device and on the other hand 
from the vascular elasticity of the vascular wa11.i2 In the 
unconstrained state the maximal diameter ranged from 3.5 
to 6 mm (mean 4.2 mm) with a length that varied from 15 
to 30 mm (mean 22 mm). Before implantation the stent was 
stretched and mounted on the tip of a 5F central-hole 
catheter; subsequently the device was covered by a coaxial 
balloon that was removed during the procedure. To ascer- 
tain continuous outward compression of the vascular wall 
after implantation, the unconstrained diameter of the stent 
was chosen to exceed the measured reference diameter of 
the stenosed area by approximately 0.5 mm. 
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implantation, baseline coagulation status and bleeding 
time were evaluated in all patients. Bleeding time was de- 
termined according to the method of Hemker et al.‘” 
Thrombocytes were counted by means of an automated 
whole hlood platelet analyzer (Serono-Baker Diagnostics, 
Allentown, Pa.). APTT was determined with activated 
cephaloplastin reagent (Actin, Merz and Dade AG, Diidin- 
gen, Switzerland); prothrombin time (PT) was obtained by 
the method of Quick’” with calibrated thromboplastin 
reagent.” In addition, fihrinogen levels were determined in 
citrate plasma by means of thrombin solution (Thrombin, 
Hoffmann-La Troche & Co., Basel, Switzerland) according 
to the method of Claussls; Factor V levels were measured 
in citrate plasma by means of human thromboplastin 
reagent (Thromborel S, Behringwerke AG, Marburg, West 
Germany). 
Thromhotest, consisting of ox brain thromboplastin de- 
void of coagulation factors, was used to adjust the dosage 
of oral anticoagulation therapy; it is a modified PT assay 
that is sensitive to reduced levels of coagulation factors II, 
VII, and X and the presence of protein-induced by the ab- 
sence of vitamin K or antagonists that result from antico- 
agulation therapy. I9 In view of the lack of standardization 
of PT determinations, the primary standard (World Health 
Organization international thromboplast,in) was recently 
calibrated against three secondary standards among which 
ox brain thromboplastin (Thrombotest), the international 
normalized ratio that was subsequently assigned to each 
preparation, facilitates comparison of results obtained by 
each method.20, “I 
According to the TT, coagulation activity was expressed 
as a percentage of control activity. In the presence of ane- 
mia or polycythemia, the values were corrected according 
to the specifications of the assay. TT measurements may 
seemingly be lowered during concomitant heparin admin- 
istration; in our patients this effect was not compensated 
for by neutralization of serum samples with protamine 
sulfate.“” Instead TT was determined daily until heparin 
was gradually discontinued when TT values were within 
the therapeutic range. 
RESULTS 
Stent implantation. The angiographic results after 
stent implantation were evaluated by means of quan- 
titative angiography, with an automated edge-detec- 
tion technique. I49 23-2.5 Before balloon dilatation the 
mean luminal diameter of the stenosed bypass was 
1.5 mm + 0.9 (range 0.7 to 2.9). The mean estimated 
reference bypass diameter at the stenosis (interpo- 
lated technique) was 3.4 mm + 1.1 (range 1.6 to 7.0), 
and the average diameter of the angioplasty balloon 
was 3.2 mm & 0.6 (range 2 to 4.2). The unconstrained 
diameter of the stent that was implanted after 
balloon dilatation was 4.1 mm +- 0.7 (range 3.5 to 
6.0). All procedures were successful and without 
complications. The procedure allowed easy delivery 
of the device without misplacement and reduced the 
diameter of the stenosis to <50%. There were no 
Table II. Drug treatment protocol 
Salicylic acid, lOOO/lOO mg daily 
Dipyridamole, 300 mg daily 
Sulfinpyrazone, 800 mg daily 
Nif’edipine. 60 mg daily 
Urokinase, 100,000 to 250,000 117 * 
Heparin >lOOO IU/kg/hr w 
(guided hy APTT) 
Acenocoumarol v 
(guided by TT or Quick test 1 
acute bypass occlusions. Immediately after angio- 
plasty and stent implantation, the mean diameter of 
the lesion was 2.0 ( + 0.6) and 2.8 ( -t 0.9) mm, respec- 
tively. 
Baseline hemostatic parameters. Baseline coagula- 
tion parameters are summarized in Table III. Before 
stent implantation, TT, PT, and APTT were all out- 
side the normal range, which was accounted for 
treatment with oral or intravenous anticoagulants in 
almost half of the patients (see Drug protocol before, 
during, and after implantation.) Fibrinogen levels 
were strikingly elevated as well. The changes in the 
coagulation parameters during and after stent im- 
plantation are shown in Fig. 1. Initially the mean 
APTT (closed circles, SEM as bars) increased to 120 
seconds and thereafter stabilized around 80 seconds. 
As soon as the thrombotest values had decreased be- 
tween 5 % and 10 % on days 2 to 3, heparin was grad- 
ually discontinued, resulting in normalization of the 
APTT. Note that two patients had early occlusion of 
the stented graft. In patient A the occlusion (day 2) 
coincided with suboptimal anticoagulation treat- 
ment; in patient B anticoagulants had to be discon- 
tinued on day 7 after implantation as a result of acute 
gastrointestinal bleeding (see below). 
Comptications (Table IV). Four patients had he- 
matomas with a diameter exceeding 5 cm, resulting 
in anemia that had to be corrected by blood transfu- 
sions. One patient had a transient attack, but fortu- 
nately the clinical condition normalized without 
sequelae. As mentioned previously patient A, who 
initially had two stents implanted, had a recurrence 
of angina pectoris after 3 months; results of repeat 
angiography showed severe stenosis proximal to the 
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Fig. 1. Mean activated partial thromboplastin time (APTT in seconds [O]) and thrombotest (TT in [, 
[0]) of patients before and after stent implantation (mean t SEM). A and B indicate actual APTT and 
TT in two patients at time of acute thrombotic occlusion. 
Table III. Baseline coagulation status 
Parameter 
Bleeding time (l-4 min) 
Thrombocytes (130-350* 1 OEg/L) 
APTT (22-45 set) 
PT (14-19 set) 
TT (65”&150”,. 1 
NT (65’~ -llO”, ) 
Fibrinogen (1.6-2.8 gm/L) 
Factor V (0.5-1.5 E/ml) 
2.1 ir 0.8 
220 -t 45 
45 k :37 
22 i 8 
51 t 30 
78 k 43 
x.4 * 0.7 
1.3 I!z 0.4 
APTT. activated partial thromhoplastin time; NT. normotest; PT. prw 
thrombin time; TT. thrombotest. 
implanted stents. This was corrected by balloon an- 
gioplasty followed by implantation of two additional 
stents. However, 3 days later the patient again had 
angina. Results of recatheterization showed that the 
peripheral native vessels supplied by the stented by- 
pass graft showed thrombi that were not present on 
the angiogram before the second implantation. Sub- 
sequently it was decided to perform a reoperation, 
which was uneventful. 
Patient B (Fig. 2) had upper gastrointestinal 
bleeding in spite of the absence of gastrointestinal 
complaints before the intervention. As a result of 
continuous vomiting with blood loss and melena, 
heparin and acenocoumarol were discontinued, Sub- 
sequently the patient had angina with ECG signs of 
myocardial ischemia (i.e., negative T waves) without 
elevation of creatine kinase levels. During recathe- 
terization it appeared that this was related to im- 
pending occlusion of the bypass by a fresh thrombus 
located outside the stented segment. Subsequently, 
repeat coronary bypass surgery was performed with- 
out evidence of perioperative myocardial infarction. 
A third patient had an uneventful implantation of 
one stent. However, on day 7 he had an acute myo- 
cardial infarction (maximal creatine kinase level, 706 
U/L) without signs of congestive heart failure. Re- 
sults of recatheterization showed total occlusion of 
the bypass within the stent, notwithstanding ade- 
quate anticoagulation therapy. In one patient con- 
tinued blood loss from the sutured brachial artery 
necessitated surgical reexploration; a false aneurysm 
of the brachial artery was sutured and the vessel re- 
constructed by means of a venous flap. The subse- 
quent clinical course was uneventful, and the patient 
was given anticoagulants and discharged. One pa- 
tient had hematuria without anemia. 
DISCUSSION 
Short-term follow-up after dent implantation. Our re- 
sults show that stent implantation after balloon 
angioplasty of stenosed venous bypass grafts is tech- 
nically feasible and successful at an early stage, pro- 
vided that the patients are carefully selected. To be 
a candidate for stent implantation, each patient was 
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Table IV. Complications of stent implantation 
Complication N 
No complications 12 
Hematoma 3 
Infected 1 
Groin hematoma (intermediate) 3 
Groin hematoma (excessive) 4 
with transfusion 
Hematuria 1 
Phlebitis 1 
Recurrent angina resulting from native 1 
coronary artery disease 
Intrahospital myocardial infarction in native 1 
vessels (ejection fraction 0.62’C8 - >0.36’, ) 
Vascular surgery for bleeding 1 
cuhital false aneurysm 
screened for the presence of all possible contraindi- 
cations for anticoagulation therapy. Therefore possi- 
ble bleeding disorders, notably upper or lower gas- 
trointestinal bleeding as a result of ulcers, gastritis, 
esophageal varices, or Mallory-Weiss syndrome, had 
to be ruled out. Other disorders that precluded stent 
implantation were any recent bleeding, cerebral hem- 
orrhage, severe liver or kidney dysfunction, throm- 
bocyte dysfunction, thrombocytopenia, or hyperten- 
sion (> 180/l 10 mm Hg), and diabetic or hypertensive 
retinopathy. For this reason complete hematologic 
and coagulation status was obtained from all patients 
before the intervention, and stool samples were 
checked for the presence of microscopic blood loss. 
Notwithstanding these precautions, one patient had 
upper gastrointestinal bleeding, necessitating inter- 
ruption of the anticoagulation therapy. 
Another important determinant of the ultimate 
success is the regional anatomy of the coronary 
arteries that are supplied by the diseased venous by- 
pass graft. In our previous experience with stenting 
of coronary arteries, poor distal runoff, small diam- 
eter of the stenosed vessel, and previous myocardial 
infarction in the region supplied by the stenosed ar- 
tery, as well as haziness of the dilated lesion, were 
contraindications for stent implantation. Our favor- 
able results within the first day may be explained, at 
least in part, by the diameter of the venous grafts, 
which exceeded the luminal diameter of native cor- 
onary vessels by a factor of 1.5 to 3. 
In general the extensive anticoagulation therapy 
was continued until 3 months after stent implanta- 
tion. The rationale for this approach is based on 
observations in animal experiments; it has been 
reported that stents that were implanted in pig fem- 
oral arteries were completely covered by endothelium 
within 1 to 3 weeks. 26 Since histologic data in humans 
Fig. 2. Coronary angiogram (patient B) of venous bypass 
graft connected to left anterior descending coronary artery, 
immediately after successful stent implantation (a) and 
during acute occlusion (b), showing impending occlusion of 
bypass graft by fresh thrombus located outside stented 
segment (arrow). 
are still lacking, we decided not to risk acute throm- 
botic occlusion and therefore continued anticoagula- 
tion therapy until 3 months after implantation. 
Stringent anticoagulation was accomplished by scru- 
pulous and frequent monitoring of the coagulation 
status of each patient for approximately 3 months. It 
is conceivable that in some patients the burden of 
frequent visits to the outpatient clinic and extensive 
medication may compromise the quality of life to 
such an extent that it would have been preferable to 
perform bypass surgery despite the possibility of in- 
creased risk of myocardial infarction or even death as 
a result of the latter procedure. The possible advan- 
tageous long-term effects of stent implantation on 
the rate of restenosis should be well established to 
gain acceptance as an alternative to bypass surgery. 
Thus long-term follow-up including quantitative an- 
giography of treated patients is necessary and is cur- 
rently under investigation. 
Hemostatic monitoring: Theoretic and practical con- 
siderations. The adequacy of anticoagulation therapy 
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was controlled by assessing the TT (in percentages) 
and APTT levels (in seconds). The concept of the 
thrombotest was initially introduced by Owren.lg It 
is well known that coumarin derivatives, such as 
acenocoumarol or phenprocoumon, prevent incorpo- 
ration of vitamin K in coagulation factors II, VII, IX, 
and X. Consequently inactive proteins induced by 
the absence of vitamin K (or antagonists) are 
formed.16 The resulting lengthening of coagulation 
time may be measured by means of the thrombotest; 
the test assesses the serum coagulation time in the 
presence of excess kefaline, thrombokinase, factors V 
and VIII, and calcium chloride. The assay is sensitive 
to the presence of coagulation factors II, VII, (IX), 
and X and is more or less equivalent to the PT as 
measured by the Quick test. Normal thrombotest 
values of 40 seconds or less have been reported in 
healthy control subjects; in our patients the prefer- 
able TT level ranged between 180 and 210 seconds, 
which is equivalent to a thrombotest value of 5% to 
10% (international normalized ratio 2.5 to 5). Ac- 
cording to the manufacturer, thrombotest values 
may be seemingly increased in the presence of 
heparin. 22 Although this does not seem relevant in 
daily clinical practice, this effect may be compen- 
sated for by neutralization of the serum before the 
test. We preferred to gradually discontinue heparin 
administration and frequently monitored TT at the 
same time. 
plications may have resulted from local thrombo- 
genie mechanisms that were triggered by the inter- 
action of the self-expanding stent with the more 
compliant vessel wall. To prevent these acute throm- 
botic complications, we applied stringent anticoagu- 
lation therapy after successful implantation of the 
stent. The rationale for the drug treatment was to 
provide maximal antithrombotic effects by interfer- 
ence with the normal function of platelets and 
endothelial lining and by inhibition of coagulation 
factors. 
The effect of heparin administration was adjusted 
according to the APTT. The patient’s pretreatment 
APTT (30 to 35 seconds) was increased by a factor of 
2 or 3. The white cell count appeared elevated after 
the procedure in almost every patient; this may have 
been caused by acenocoumarol, which may induce 
redistribution of white cells, notably neutrophils, as 
has been reported recently.27 However, in our pa- 
tients the observed leukocytosis may be equally well 
accounted for by hematoma formation and subse- 
quent resorption. 
As a result of stent implantation the intimal lining 
of the venous graft was damaged, which may have 
given rise to aggregation of platelets and formation of 
thrombin.28 Therefore platelet aggregation was an- 
tagonized by aspirin and sulfinpyrazone, both of 
which inhibit production of thromboxane Agzg, :j”; 
dipyridamole, on the other hand, was administered in 
an attempt to inhibit platelet deposition and aggre- 
gation to damaged vessels because of increased pro- 
duction of platelet c-AMP.~I, 32 Thrombin formation 
was prevented by administration of heparin and if 
present lysed by urokinase, thereby preventing acute 
occlusion.33, 34 Vasospasm, which may be triggered by 
release of vasoactive agents during angioplasty, was 
prevented by nifedipine and diltiazem.3” Dextran 
(Rheomacrodex) was infused, since this inert plasma 
volume expander is known to reduce platelet adhe- 
siveness and platelet aggregation induced by injury 
to the vessel wa11.36, 37 In addition, it reduces factor 
VIII activity38 and increases clot lysability.“g It 
remains to be seen whether this extensive anticoag- 
ulation regimen is an absolute requirement for pre- 
vention of the complications of acute thrombosis. A 
less extensive protocol may appear equally effective 
for prevention of early thrombotic complications af- 
ter stent implantation in venous bypass grafts.40 In 
addition, the number of patients with complications 
induced by the stringent anticoagulation regimen 
may be reduced. 
We conclude that stent implantation after per- The stents that were implanted in our patients 
cutaneous transluminal coronary angioplasty of were not coated. It has been reported that heparin- 
stenosed venous bypass grafts may result in normal- or polymer-coated stents may be advantageous, since 
ization of the regional hemodynamic profile. Unfor- endothelial cell proliferation is enhanced by various 
tunately the drastic improvement in rheologic con- anticoagulation and antiplatelet drugs, as was shown 
ditions, as evidenced by the virtual disappearance of in cell cultures. Notably low-molecular-weight hep- 
poisseuille resistance and normalization of laminar arin seems to exert a favorable effect on endothelial 
flow,14 was inadequate to prevent thrombotic com- cell growth. 41 Future designs for stents should in- 
plications in three patients. Our observations there- clude polished endings for the wires that form the 
fore suggest that the primary cause of thrombotic device; alternatively the device could be covered by 
occlusion must be ascribed to the thrombogenic na- a layer of endothelial cells or polymer or corticoid 
ture of the stent itself or to its direct thrombogenic coating to prevent early thrombotic occlusion and 
interaction with the diseased and atherosclerotic endothelial proliferation for the longer term.4” More 
vessel wall. Likewise the observed thrombotic com- recently it has been suggested that the device be cov- 
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ered with heparin benzalkonium chloride complex 
(H-BAC), which is known to prevent thrombosis. 
Other designs such as biodegradable devices, may 
also prove useful and diminish the rate of restenosis. 
To prevent some of the bleeding complications, 
anticoagulation therapy, notably acenocoumarin, 
may be considered 1 day before stent implantation. 
Likewise removal of the arterial sheaths immediately 
after the procedure rather than 12 hours later could 
reduce the number of severe hematomas. 
Recently it was suggested that the effects of hep- 
arin administration be monitored by measurement of 
activated clotting time during and after percutane- 
ous transluminal angioplasty.43 The same technique 
could be applied equally well in patients after stent 
implantation. Since the method is reliable, cheap, 
and easy to perform, it may be considered more fre- 
quently to adjust heparin administration and attain 
an optimal coagulation status. Introduction and ap- 
plication of these and other laboratory techniques 
without any doubt will reduce the risk of thrombotic 
occlusions resulting from inadequate heparin admin- 
istration. 
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